Administration of the popular anti-inflammatory drug Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) in combination with Lipitor (atorvastatin, a cholesterol lowering drug or statin) halts the transition of early prostate cancer to its more aggressive and potentially deadly stage.
“Anti-androgen therapy slows the prostate cancer but eventually the cancer becomes androgen-independent, the therapy becomes ineffective and the cancer cells become more aggressive,” said Xi Zheng, assistant research professor at Rutgers, The State University of New Jersey, who conducted the study.
“Treatments available for the later stage cancers are not very good,” said Allan Conney, director of Rutgers’ Susan Lehman Cullman Laboratory for Cancer …read more